TY - JOUR
T1 - Activation of human NK cells and monocytes with cisplatin in vitro
AU - Sodhi, Ajit
AU - Pai, Kalpana
AU - Singh, Rakesh Kumar
AU - Singh, Sukh Mahendra
N1 - Funding Information:
Acknowledgements -- This work has been supported with grants from the University Grants Commission and Indian Council of Medical Research, New Delhi. Some financial assistance from the School of Biotechnology, B.H.U. is also acknowledged. Dr Sukh Mahendra Singh is a Scientific Pool Officer of the Council for Scientific and Industrial Research, New Delhi.
PY - 1990
Y1 - 1990
N2 - Human natural killer (NK) cells and monocytes treated in vitro concomitantly with cisplatin and rIFN-γ enhanced lysis of K562 cells. Lysis was dependent upon the duration of treatment. Cisplatin and rIFN-γ treated monocytes were equally cytotoxic to NK sensitive (K562) and NK resistant (Daudi & Raji) cell lines whereas NK cells were not rendered cytotoxic against NK resistant tumor cells. NK- and monocyte-mediated cytotoxicity against K562 cells was further enhanced when the effector cells were primed with rIFN-γ and were subsequently treated with cisplatin.
AB - Human natural killer (NK) cells and monocytes treated in vitro concomitantly with cisplatin and rIFN-γ enhanced lysis of K562 cells. Lysis was dependent upon the duration of treatment. Cisplatin and rIFN-γ treated monocytes were equally cytotoxic to NK sensitive (K562) and NK resistant (Daudi & Raji) cell lines whereas NK cells were not rendered cytotoxic against NK resistant tumor cells. NK- and monocyte-mediated cytotoxicity against K562 cells was further enhanced when the effector cells were primed with rIFN-γ and were subsequently treated with cisplatin.
UR - http://www.scopus.com/inward/record.url?scp=0025572458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025572458&partnerID=8YFLogxK
U2 - 10.1016/0192-0561(90)90008-B
DO - 10.1016/0192-0561(90)90008-B
M3 - Article
C2 - 2127263
AN - SCOPUS:0025572458
SN - 1567-5769
VL - 12
SP - 893
EP - 898
JO - International Immunopharmacology
JF - International Immunopharmacology
IS - 8
ER -